U.S. regulators actually delivered good news to Idenix Friday: Lifting a clinical hold placed on IDX-184 which will allow the company to push the hepatitis C drug ahead into further studies.
Yet Idenix shares are off 10% to $11.91 because IDX-184's future is cloudier in light of Gilead's announcement last night of new data showing 100% of genotype 1 hepatitis C patients treated with the experimental pill GS-7977 plus ribavirin had no evidence of the virus after four weeks of treatment.
These new Gilead data further bolstered the most optimistic view that a simple two-pill combination of GS-7977 and ribavirin will be strong enough to cure hepatitis in a majority of infected patients in the U.S. and Europe.And if Gilead can be first to grab the majority of future treatments for hepatitis C patients starting in 2014, that doesn't leave much left for Idenix and IDX184. "If GS7977 plus ribavirin is all you need, then IDX-184 is in trouble because it's already seen as a weaker drug. It's more likely that to be effective, IDX184 will need to be combined with two other drugs," said one hedge fund manager who owns Gilead but doesn't own Idenix and is not short the stock. Idenix has not yet started hepatitis C studies that combine IDX184 with other oral drugs although the company said Friday that these studies would start soon now that FDA has lifted its clinical hold. Still Idenix's efforts are lagging Gilead as well as other competitors like Bristol-Myers Squibb (BMY) and Abbott (ABT). Even with Friday's sell off, Idenix shares are up about 60% since the beginning of the year on takeout speculation and the investor frenzy around hepatitis C drug development. With Pharmasset acquired for $11 billion by Gilead and Bristol buying Inhibitex (INHX) for $2.5 billion, it's not inconceivable that another drug maker desperate to stay relevant in the lucrative hepatitis C drug race decides to roll the dice and buy Idenix. "I'm not a fan of IDX184 but I'm also not brave enough to short Idenix," said another hedge fund manager.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV